ON DEMAND Nuclear 2025

Course overview

Upon completion of this activity, participants will be able to: Describe the pathophysiology, epidemiology, and treatment of renal cell carcinoma (RCC); : Review key components of UPS 825 and how to respond to corresponding audit questions during an inspection; Identify key radiation hazards and safety risks; List isotopes with long-lived radioactive impurities: focus on Ac 225, Pb 212 and At-211; Evaluate how the radiopharmaceutical research pipeline has changed over time: Number of trials by disease state, Diagnostic vs Therapeutic, By isotope; Determine the statistical variation encountered in a typical nuclear counting experiment (precision and chi square); Define the role of nuclear CMOs and CDMOs in radiopharmaceutical development and production; Compare and contrast Ga-68 DOTATE PET/CT and 123 I-MIBG SPECT/CT in terms of mechanism, biodistribution, sensitivity, and clinical use across NET subtypes.